<DOC>
	<DOCNO>NCT02563860</DOCNO>
	<brief_summary>This phase 2 , open label , dose escalate study Lovastatin Rett syndrome .</brief_summary>
	<brief_title>Pharmacological Treatment Rett Syndrome With Statins</brief_title>
	<detailed_description>Excess neuronal cholesterol play role pathophysiology Rett syndrome ( RTT ) investigator hypothesise inhibition cholesterol synthesis CNS reduce neuronal cholesterol lead improvement Rett syndrome relate symptom . Goal : To determine optimal dose regiment Lovastatin patient RTT identify appropriate primary outcome measure subsequent Phase 3 study . Phase 2 , dose escalation study . Primary outcome : Gait speed Secondary outcome : respiratory function , cognition , EEG ( encephalopathy ) , Rett syndrome severity scale , neurodevelopmental assessment ( QOL ) 20 ambulatory female patient genetically confirm .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Females patient , Genetically confirm RTT , Ambulatory . Presence co morbid nonRett related disease , History adverse reaction/hypersensitivity statin , Levels aspartateamino transferase ( AST ) , alanineamino transferase ( ALT ) creatine kinase ( CK ) triple normal value , Active liver disease , Concomitant use strong CYP3A4 inhibitor , Condition predispose renal failure secondary rhabdomyolysis ( scoliosis surgery within 6 month ) , Oral contraceptives use .</criteria>
	<gender>Female</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>